Evoke Neuroscience aims to develop Artificial Intelligence biomarker for Alzheimer’s disease diagnosis
NEW YORK, NY, USA, November 8, 2019 /EINPresswire.com/ — Evoke Neuroscience, a medical device company developing and commercializing technologies to aid in diagnosis of cognitive disorders, announced today initial enrollment of subjects participating in an IRB approved study to develop an Artificial Intelligence (AI) biomarker of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conducted at the Pacific Neuroscience Institute […]
Allied : Signs Letter of Intent with Evoke Neurosciences to Partner on the Analysis and Treatment of PTSD Patients
Allied Corp. (OTC Pink: ALID) (“Allied”), an international medical cannabis production company focused on creating and providing targeted cannabinoid health solutions, is pleased to announce its signing of a Letter Of Intent (“the LOI”) with Evoke Neurosciences (“Evoke”). Evoke’s eVox System generates an objective and automated report for clinicians and researchers to use as a baseline and to aid diagnosis […]
Evoke Neuroscience takes on TBI, PTSD with the US Air Force
NEW YORK CITY, NY, USA, September 10, 2019 /EINPresswire.com/ — Evoke Neuroscience has been awarded a working contract by the United States Air Force (USAF) for its diagnostic device, the eVox® System. The contract is part of the USAF Small Business Innovation Research (SBIR) Phase I program that provides the framework for a fully integrated solution with Air Force constituents. […]
Evoke Neuroscience to Present at ROTH Capital Conference
Evoke Neuroscience announces it has been selected to present to the attendees of this year’s ROTH Capital Conference on March 18 in Orange County, California. Evoke will present its eVox® System, the FDA-cleared device that aids physicians in the diagnosis of memory loss and other cognitive disorders, to a diverse group of clinicians, investors, and healthcare industry professionals. Evoke has […]
Evoke Neuroscience awarded People’s Choice Award at OCTANe’s Medical Technology Innovation Forum
NEW YORK, NEW YORK, USA, November 8, 2018 /EINPresswire.com/ – Evoke Neuroscience won the popular vote by attendees and took home the People’s Choice Award at OCTANe’s 13th Annual Medical Technology Innovation Forum. Recognized for its bold vision of eradicating dementia, Evoke Neuroscience was one of 8 companies selected out of 113 who applied to present via the OCTANe LaunchPad […]
Evoke Neuroscience to present at OCTANe’s 13th Annual Medical Technology Innovation Forum
NEW YORK, NY, USA, October 11, 2018 /EINPresswire.com/ – Evoke Neuroscience announces it has been selected to present to the attendees of this year’s Medical Technology Innovation Forum on October 29th in Newport Beach, California. Evoke will present its eVox System, which aids physicians in the diagnosis of memory loss and other cognitive disorders, to a diverse group of clinicians, […]
Evoke Neuroscience awarded Breakthrough Technology agreement with Premier
New York, NY, March 29, 2018 – Evoke Neuroscience has been awarded a group purchasing agreement as a breakthrough technology with Premier. Effective March 1, 2018, the agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for the eVox® System, the medical device that assesses brain function to aid doctors in the diagnosis of […]
Evoke Neuroscience announces award of VA contract for the eVox® System
Evoke Neuroscience, Inc. is pleased to announce the award of a Veterans Health Administration Contract for the eVox® System. The Contract award #36F79718D0348 enables the VA and other federal organizations to purchase the eVox System at pre-approved pricing via the Veterans Administration’s FSS Contract, via GSA Advantage, or GSA eBUY. The eVox System measures brain health to aid doctors in […]
CISION iREACH
CISION iREACH – September 14, 2017 Evoke Neuroscience named to Inc. 5000 List of America’s Fastest-Growing Private Companies for Second Consecutive Year. Read the Full Article
The Silicon Review
The Silicon Review – May 15, 2017 Evoke Neuroscience named as one of 50 most valuable brands of the year 2017. Read the Full Article
The eVox system is a Class II medical device that has received Section 510(K) clearance from the FDA. It is intended for the acquisition, display, and storage, of electrical activity of a patient’s brain including electroencephalograph (EEG) and event-related potentials (ERP) obtained by placing two or more electrodes on the head to aid in diagnosis.
Inc. 500
TransTech 200
ISO
SharpBrains
The eVox System®
Waveband®
Evoke Wave™
Dr. David Hagedorn is experienced in clinical health psychology and neuropsychology and serves as an international neuroscience and biofeedback research consultant and instructor.
Eileen Sukumaran is a seasoned operations executive with 18 years of specialized experience in the FDA regulated medical device industry. 
Dr. James Thompson holds both a master’s degree and a doctorate degree in Kinesiology (specializing in sports-related brain injury) and Psychophysiology from Pennsylvania State University. He also holds a Bachelor of Science degree in Human Kinetics (Athletic Training and Rehabilitation). He is a Certified Kinesiologist with the Canadian Kinesiology Association, board certified in Neurofeedback, and is an Associate Fellow of the Biofeedback Certification International Alliance.
Dr. Nicole Hagedorn is a graduate of the United States Military Academy at West Point where she earned the title of Commissioned Officer in the U.S. Army. She is also a graduate of the Michigan State University College of Osteopathic Medicine.
Marinela Gombosev is President and CEO of Evoke Neuroscience, a medical diagnostic technology company that has twice been ranked in the Inc. 500|5000 fastest growing private companies. Evoke develops diagnostic technology that aids physicians in diagnosis of memory loss, Alzheimer's, dementia and other cognitive disorders. Marinela Gombosev has nearly 15 years of leadership experience scaling operations, product development and execution of marketing strategies in regulated industries. Previously, Ms. Gombosev was at BIT Group where she led cross-functional teams on a product development effort of a Class II medical diagnostic device in preparation for global commercial launch.
John Armstrong has 25 years of experience in various sales and marketing roles. Prior to joining Evoke Neuroscience, Mr. Armstrong served as Senior Vice President of Commercial Operations at Bentlin Products. He also served as Senior National Sales Director/Head of Sales at Accera, Inc., where he was responsible for leading the sales, training, and sales operations teams in the Alzheimer’s disease franchise. Mr. Armstrong has also worked at Bristol-Myers Squibb in a variety of sales leadership, sales, sales training, and marketing roles that focused on selling pharmaceutical products to doctors, hospitals, and clinics. Mr. Armstrong is a graduate of the University of Florida with a Bachelor of Arts degree in Political Science, and served in the United States Navy as a Cryptologist for four years.
Dr. Michael A. Repucci received a Ph.D. in neuroscience in 2004 from the Weill Graduate School of Medical Science at Cornell University for work on the nonlinear dynamics in the visual system. He has worked in the field of EEG data analysis since 1999, In his graduate work, he received extensive training in experimental and computational techniques, and significant experience in software design and development. In his subsequent work in several research laboratories and as an independent scientific consultant, he gained further experience in software development and statistical analysis, from work in finance on trading strategies to lead developer on the Spike Train Analysis Toolkit. He has created tools for scientific research with languages including C/C++/C#, Java, Matlab, and Python. In his recent work, he leveraged this strong background in neuroscience, computational methods, and software development to guide the design and implementation of novel brain-computer interface technologies at Neuromatters, and now leads the software development of the flagship QEEG and neurofeedback platform, the eVox System, at Evoke Neuroscience.
Gordon Smith has been a leader of technology organizations for over two decades. His experience includes technology staff and infrastructure management, software design and development, systems analysis, and project management. Mr. Smith is experienced in delivering intellectual property and infrastructure for startups, growing firms, and multinational corporations. Mr. Smith has worked at and performed consulting services for Goldman Sachs, Merrill Lynch, The New York Stock Exchange, and Towers Watson. He was also a member of the board of directors of Members Alliance Insurance.
Dr. Felipe Fregni is the Director of the Laboratory of Neuromodulation at Spaulding Rehabilitation Hospital and Associate Professor of Neurology and Physical Medicine and Rehabilitation at Harvard Medical School. His research is focused on understanding neuroplastic changes associated with conditions such as chronic pain, Parkinson’s disease, and stroke, using non-invasive brain stimulation as an investigative tool for such aims.
Dr. John Polich is dedicated to developing event-related brain potentials (ERPs) and other neuroelectric measures for the assessment of human cognition. His current research focuses on assessing the acute and chronic effects of drug use, neurologic disorders, and basic information processes studies on frontal lobe function.
Dr. Pamela Hyde is a Board Certified by the American Board of Osteopathic Obstetricians and Gynecologists (FACOOG) as well as Anti-Aging and Regenerative Medicine holding the distinction of Advanced Fellow. With a BS from the University of Maryland in Nutrition Research, Dr. Hyde continues the pursuit of health and wellness and is enrolled in the University of South Florida Master’s Degree in Medical Sciences with a Concentration in Metabolic & Nutritional Medicine. After her Active Duty Military commitment, Dr. Hyde moved to southwest Oklahoma in January 2001; and continues as an Active Reservist in the U.S. Air Force. Dr. Hyde has always had a passion for the underserved and has severed on humanitarian missions to Nicaragua and Afghanistan. She is active in the community giving seminars on Healthy lifestyle, Disease Prevention, Stress Reduction, and Hormone Replacement.
Dr. David Haase is board certified in Family Medicine and Integrative Holistic Medicine and is an IFM Certified Functional Medicine Practitioner. Dr. Haase is a recognized expert in the field of non-invasive brain assessment and advanced neuro-performance. He created the QEEG and neurofeedback section of the first US Medical School sponsored Brain Health certification program. He teaches physicians internationally about how the brain is the center of Quality of Life, and a better understanding of the brain is the key to improve patient outcomes.
Dr. Dirk de Ridder is the Neurological Foundation Chair of Neurosurgery at the University of Otago in New Zealand. In his clinical capacity, Dr. Ridder is responsible for skull base surgery, and microvascular decompression surgery. His research interests are centered on a Darwinian predictive brain model with Bayesian updating to adapt to an ever changing environment. This model is the basis to understand common pathophysiological mechanisms clustering groups of pathologies, such as thalamocortical dysrhythmias (pain, tinnitus, epilepsy, depression, Parkinson's disease, schizophrenia) or obsessive compulsive spectrum disorder (such as addiction, OCD, or eating disorders).
The Silicon Review
Peter E. Raymond has spent the last two decades solving problems, by combining emerging technology with design and innovative, yet robust business models. His award-winning work in health care has spanned the globe, and he was selected to develop the Bill and Melinda Gates Foundation's global communications strategy as Warren Buffet's gift was endowed.
Dr. Morgan Ingemanson holds a doctorate degree in Anatomy and Neurobiology and has specialty training in functional neuroimaging. She has led clinical trials focused on neural repair after central nervous system injury in humans, utilizing tools including anatomical brain imaging, functional MRI, dense-array EEG, and transcranial magnetic stimulation (TMS). In her doctoral work at University of California, Irvine, a major emphasis was placed on translating new drugs and devices to reduce disability after CNS injury, and on individualizing therapy for each patient’s needs. At Evoke Neuroscience, Dr. Ingemanson is the leading expert in computational EEG/ERP neuroimaging biomarkers and is the Principal Investigator for ongoing Research & Development efforts.